EZH2 and prostate cancer: Furthermore, in mouse and human prostate cancer organoids models, inhibition of EZH2 also increases the expression of the Th1 attracting chemokines CXCL9 and CXCL10 as well as Th1 cytokines including IL-2 and IL-12, which enhances CD4+ and CD8+ T cells infiltration in the TME and sensitizes prostate cancer to anti-PD1 therapy 117.